Recursion Pharma’s May update is the primary near-term driver of its stock. The company ended 2024 with $60M in cash, providing runway till 2027. Get the data-driven signals to profit from September ...

Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the acquisition of Rallybio’s full stake in their joint venture earlier this ...